Informed consent for pharmacogenomic (PGx) testing to guide medication selection and dosing. Covers genes and drug-metabolism pathways tested, incidental findings policy, family implications, GINA employment/life-insurance protections, data sharing, and result validity over time. Patient signer.
The Pharmacogenomic Testing Informed Consent is a ready-to-use healthcare & wellness template you can send for signature in minutes. It is written for 1 signer (patient) and, by default, expires 30 days after it is sent if left unsigned. It covers consent, healthcare, genetics, pharmacogenomics, pgx, drug metabolism. Like every Abundera Sign template it is a convenience draft structured for ESIGN Act and UETA compliance, not a substitute for legal advice. Each signed copy is sealed with PAdES-LTA digital signatures, dual RFC 3161 timestamps, and a tamper-evident evidence package in WORM storage.
Document Preview
# Pharmacogenomic Testing Informed Consent > **Important — not medical advice.** For use by a licensed provider; tailor to the patient, your protocols, and state law. **Date:** ___________ **Healthcare Organization / Pharmacy / Clinic:** ___________ **Ordering Provider:** ___________ **Patient Name:** ___________ **Date of Birth:** ___________ **Medical Record Number:** ___________ **Clinical Indication for Testing:** ___________ *E.g., starting an antidepressant, antiplatelet therapy, pain management, chemotherapy, cardiovascular medication, antiepileptic, or general medication optimization* --- ## 1. What Is Pharmacogenomic Testing? Pharmacogenomics (PGx) is the study of how a person's genetic makeup affects their response to medications. Variations in certain genes alter how the body absorbs, metabolizes, distributes, or responds to drugs. By identifying your genetic profile in these genes, your provider can select medications and doses more likely to be effective and less likely to cause adverse effects for you specifically. PGx testing is a one-time test. Because your DNA does not change, results remain valid for a lifetime and can be used to guide future medication decisions — provided that scientific understanding of the relevant gene-drug interactions is current at the time of use. --- ## 2. Genes and Drug-Metabolism Pathways Tested The specific genes tested depend on the panel ordered. Common genes and associated drug classes include: | Gene | Drug Classes Affected | Clinical Relevance | |---|---|---| | CYP2D6 | Antidepressants, antipsychotics, opioids (codeine, tramadol), beta-blockers, tamoxifen | Poor, intermediate, normal, or ultra-rapid metabolizer — affects efficacy and toxicity | | CYP2C19 | Clopidogrel (Plavix), proton pump inhibitors, SSRIs, antifungals | Poor metabolizers may have reduced clopidogrel activation → increased cardiovascular risk | | CYP2C9 | Warfarin, NSAIDs, phenytoin, sulfonylureas | Affects dosing requirements and bleeding risk | | CYP3A4/3A5 | Statins, immunosuppressants, calcium channel blockers, many others | Broad drug-metabolism pathway |